Home › Funds › MPM BioImpact LLC › BLTE
MPM BioImpact LLC position in BLTE
BELITE BIO INC · Health Care
MPM BioImpact LLC reported holding 137,208 shares of BLTE (BELITE BIO INC) in its Q2 2026 13F filing — a position valued at US$21.1M, representing 1.29% of its reported portfolio and ranking #28 among its reported holdings. MPM BioImpact LLC has disclosed BLTE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's BLTE position evolved
MPM BioImpact LLC first disclosed a stake in BLTE in Q4 2025 at 87,760 shares (US$14.0M). The position peaked in Q2 2026 at 137,208 shares, worth US$21.1M. Across 3 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 137,208 shares valued at US$21.1M — an increase of 49,163 shares quarter over quarter.. Notable position changes include a 56% increase in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 87.76K | $14.04M | New |
| Q1 2026 | 88.05K | $14.04M | Hold |
| Q2 2026 | 137.21K | $21.13M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BLTE and 13F data
BLTE (BELITE BIO INC) is a Health Care company. 68 other funds we track also report a position in BLTE — the largest reported positions include Darwin Global Management, Ltd. (US$456.6M), Paradigm Biocapital Advisors LP (US$189.8M), RTW INVESTMENTS, LP (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BLTE
- Darwin Global Management, Ltd. 3.08M sh · $456.59M · Q2 2026
- Paradigm Biocapital Advisors LP 1.23M sh · $189.84M · Q2 2026
- RTW INVESTMENTS, LP 715.33K sh · $110.15M · Q2 2026
- Maverick Capital 396.31K sh · $61.03M · Q2 2026
- MAVERICK CAPITAL LTD 396.31K sh · $61.03M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 390.83K sh · $60.18M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 357.20K sh · $55.00M · Q2 2026
- Logos Global Management LP 250.00K sh · $38.50M · Q2 2026
- Affinity Asset Advisors, LLC 165.00K sh · $25.41M · Q2 2026
- Patient Square Capital LP 110.00K sh · $16.94M · Q2 2026
- Artia Global Partners LP 24.99K sh · $3.85M · Q2 2026
- BALANCE CAPITAL PARTNERS L.P. 22.50K sh · $3.46M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held BLTE?
MPM BioImpact LLC has disclosed BLTE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is MPM BioImpact LLC's current position in BLTE?
As of Q2 2026, MPM BioImpact LLC holds 137.21K shares of BLTE (BELITE BIO INC), valued at $21.13M, representing 1.29% of its reported portfolio and ranking #28.
Has MPM BioImpact LLC been buying or selling BLTE?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC increased its position in BLTE. The position peaked in Q2 2026 at 137.21K shares.
Which other funds hold BLTE?
Other major institutional holders of BLTE include Darwin Global Management, Ltd., Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, among 68 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.